Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 167, Issue 6, pp 740–743 | Cite as

Wave-Like Dose-Dependence of the Stimulating Effects of Dimebon on Cognition in a Wide Dose Range

  • N. A. Vasilieva
  • E. F. ShevtsovaEmail author
  • G. I. Van’kin
  • N. N. Lermontova
  • T. P. Serkova
  • N. S. Nikolaeva
  • S. O. Bachurin
PHARMACOLOGY AND TOXICOLOGY

Comparison of the cognition-stimulating effects of Dimebon in a wide dose range revealed a non-monotonic and nontrivial wave-like dose-dependence of its activity. Positive results were obtained at low (0.02-0.05 mg/kg) or high (5-10 mg/kg) doses of Dimebon, while intermediate doses were ineffective. This type of the dose dependence of the pharmacological effect can indicate that the substance has several targets. This fact should be taken into consideration when selecting the doses and concentrations of the substance and its analogues for further studies, and for planning treatment schemes and administration doses in clinical studies.

Key words

cognition-stimulating effect Dimebon dose dependence multitarget effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of Dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull. Exp. Biol. Med. 2003;136(5):474-477.CrossRefGoogle Scholar
  2. 2.
    Lermontova NN1, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO. Dimebon improves learning in animals with experimental Alzheimer’s disease. Bull. Exp. Biol. Med. 2000;129(6):544-546.CrossRefGoogle Scholar
  3. 3.
    Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina NN. Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice. Neurotox. Res. 2012;22(1):33-42.CrossRefGoogle Scholar
  4. 4.
    Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases. Transl. Psychiatry. 2013;3. ID e332. doi: 10.1038/tp.2013.97CrossRefGoogle Scholar
  5. 5.
    Calabrese EJ. Alzheimer’s disease drugs: an application of the hormetic dose-response model. Crit. Rev. Toxicol. 2008;38(5):419-451.CrossRefGoogle Scholar
  6. 6.
    Calabrese EJ. Dose-response features of neuroprotective agents: an integrative summary. Crit. Rev. Toxicol. 2008;38(4):253-348.CrossRefGoogle Scholar
  7. 7.
    Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D; Dimebon investigators. Effect of Dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebocontrolled study. Lancet. 2008;372:207-215.Google Scholar
  8. 8.
    Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Muller WE. Dimebon ameliorates amyloid-β induced impairments of mitochondrial form and function. J. Alzheimers Dis. 2012;31(1):21-32.CrossRefGoogle Scholar
  9. 9.
    Makhaeva GF, Sokolov VB, Shevtsova EF, Kovaleva NV, Lushchekina SV, Boltneva NP, Rudakova EV, Aksinenko AY, Shevtsov PN, Neganova ME, Dubova LG, Bachurin SO. Focused design of polypharmacophoric neuroprotective compounds: conjugates of γ-carbolines with carbazole derivatives and tetrahydrocarbazole. Pure Appl. Chem. 2017;89(8):1167-1184.CrossRefGoogle Scholar
  10. 10.
    Schaffhauser H, Mathiasen J. R, Dicamillo A, Huffman MJ, Lu LD, McKenna BA, Qian J, Marino MJ. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem. Pharmacol. 2009;78(8):1035-1042.CrossRefGoogle Scholar
  11. 11.
    Skvortsova VI, Bachurin SO, Ustyugov AA, Kukharsky MS, Deikin AV, Buchman VL, Ninkina NN. Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy. Acta Naturae. 2018;10(4):59-62.CrossRefGoogle Scholar
  12. 12.
    Shevtsova EF, Vinogradova DV, Kireeva EG, Reddy VP, Aliev G, Bachurin SO. Dimebon attenuates the Aβ-induced mitochondrial permeabilization. Curr. Alzheimer. Res. 2014.Vol. 11(5):422-429.CrossRefGoogle Scholar
  13. 13.
    Strekalova T, Bahzenova N, Trofimov A, Schmitt-Böhrer AG, Markova N, Grigoriev V, Zamoyski V, Serkova T, Redkozubova O, Vinogradova D, Umriukhin A, Fisenko V, Lillesaar C, Shevtsova E, Sokolov V, Aksinenko A, Lesch KP, Bachurin S. Pro-neurogenic, memory-enhancing and anti-stress effects of DF302, a novel fluorine gamma-carboline derivative with multi-target mechanism of action. Mol. Neurobiol. 2018;55(1):335-349.CrossRefGoogle Scholar
  14. 14.
    Ustyugov A, Shevtsova E, Ashraf GM, Tarasov VV, Bachurin SO, Aliev G. New therapeutic property of Dimebon as a neuroprotective agent. Curr. Med. Chem. 2018;25(39):5315-5326.CrossRefGoogle Scholar
  15. 15.
    Ustyugov A, Shevtsova E, Bachurin S. Novel sites of neuroprotective action of Dimebon (Latrepirdine). Mol. Neurobiol. 2015;52(2):970-978.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • N. A. Vasilieva
    • 1
  • E. F. Shevtsova
    • 1
    Email author
  • G. I. Van’kin
    • 1
  • N. N. Lermontova
    • 1
  • T. P. Serkova
    • 1
  • N. S. Nikolaeva
    • 1
  • S. O. Bachurin
    • 1
  1. 1.Laboratory of Biomolecular Screening, Institute of Physiologically Active SubstancesRussian Academy of SciencesChernogolovkaRussia

Personalised recommendations